PRTN3 and rheumatoid arthritis: In a small trial consisting of three patients with treatment resistant RA, CD19-directed Chimeric antigen receptor (CAR)-T cell treatment caused B cell depletion and reduced the pathogenic interleukins IL-6 and TNF-α as well as RF and ACPA levels (194).